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Abstract
This review aims to provide clinicians in Latin America with the most current information on the clinical aspects, diag-
nosis, and management of Hunter syndrome, a serious and progressive disease for which specific treatment is avail-
able. Hunter syndrome is a genetic disorder where iduronate-2-sulfatase (I2S), an enzyme that degrades glycosa-
minoglycans, is absent or deficient. Clinical manifestations vary widely in severity and involve multiple organs and
tissues. An attenuated and a severe phenotype are recognized depending on the degree of cognitive impairment.
Early diagnosis is vital for disease management. Clinical signs common to children with Hunter syndrome include in-
guinal hernia, frequent ear and respiratory infections, facial dysmorphisms, macrocephaly, bone dysplasia, short
stature, sleep apnea, and behavior problems. Diagnosis is based on screening urinary glycosaminoglycans and con-
firmation by measuring I2S activity and analyzing I2S gene mutations. Idursulfase (recombinant I2S) (Elaprase®,
Shire) enzyme replacement therapy (ERT), designed to address the underlying enzyme deficiency, is approved
treatment and improves walking capacity and respiratory function, and reduces spleen and liver size and urinary
glycosaminoglycan levels. Additional measures, responding to the multi-organ manifestations, such as abdomi-
nal/inguinal hernia repair, carpal tunnel surgery, and cardiac valve replacement, should also be considered. Investi-
gational treatment options such as intrathecal ERT are active areas of research, and bone marrow transplantation is
in clinical practice. Communication among care providers, social workers, patients and families is essential to inform
and guide their decisions, establish realistic expectations, and assess patients’ responses.
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Review Article
Introduction
This review summarizes the expertise of a multi-
disciplinary group of health professionals with extensive
experience in Hunter syndrome; the aim is to provide clini-
cians in Latin America with the most current information
on the clinical aspects, diagnosis, and management of
Hunter syndrome, a serious and progressive disease for
which specific treatment is available. This review is aimed
at general practitioners and other specialists to promote
clinical suspicion, early diagnosis, and timely initiation of
appropriate therapeutic measures to help reduce the se-
quelae and irreversible damage that can occur in undetected
Hunter syndrome.
Hunter Syndrome - Characteristics of the
Disease
The mucopolysaccharidoses (MPSs) are inherited
metabolic disorders caused by genetic defects that result in
the absence or severe deficiency of one of the lysosomal
hydrolases responsible for the degradation of glycosamino-
glycans (GAGs). Part of the group of lysosomal storage dis-
orders (LSDs), all MPSs are autosomal-recessive, with the
exception of Hunter syndrome, or MPS II, which is an
X-linked recessive disease (Neufeld and Muenzer, 2001).
Hunter syndrome is caused by a deficiency of iduro-
nate-2-sulfatase (I2S, EC 3.1.6.13), which normally
cleaves a sulfate group from the GAGs, heparan and
dermatan sulfate. A shortage of I2S leads to an accumula-
tion of undegraded GAGs within the lysosomes of various
organs and tissues, including the central nervous system
(CNS) (Neufeld and Muenzer, 2001). The abnormal depo-
sition of GAGs alters the architecture and function of cells
and tissues, resulting in dysfunction of multiple organs and
systems, producing a broad spectrum of chronic and pro-
gressive clinical manifestations.
The estimated incidence of Hunter syndrome is be-
tween 0.69 and 1.19 per 100,000 live births (Alcalde-
Martin et al., 2010). In Latin America, no official data on
the incidence of MPS diseases are available; however, a
study in Portugal found that Hunter syndrome is one of the
most prevalent LSDs in the Portuguese population (Pinto et
al., 2004; Ballabio and Gieselmann, 2009). Although this
rare disorder is X-linked, thus occurring almost exclusively
in males, Hunter syndrome has also been reported in a small
group of female patients, manifesting with equal severity.
The most common mechanism for disease expression in fe-
male patients is thought to involve the process of X-chro-
mosome inactivation (Jurecka et al., 2012). The I2S gene is
located on chromosome X in the Xq28 region and, to date,
more than 300 mutations have been described (Froissart et
al., 2002; Jurecka et al., 2012). The identification of carri-
ers through mutational studies is important for genetic
counseling and prenatal diagnosis (Neufeld and Muenzer,
2001; Tuschl et al., 2005).
Patients with Hunter syndrome experience a wide
spectrum of progressive, multisystemic clinical symptoms.
Age at presentation varies, as do the symptoms and pro-
gression of disease, and there are severe and attenuated
manifestations. Symptoms in the first months of life are
usually respiratory; in addition, patients often present with
inguinal or umbilical hernia, short stature, coarse facies,
macroglossia, and gingival hyperplasia. Patients also ex-
hibit upper respiratory tract dysfunction and increased fre-
quency of recurrent respiratory infections. Another
common complication, which also occurs in other types of
MPS, is sleep apnea. Skeletal involvement occurs early in
Hunter syndrome and is characterized by dystosis multi-
plex, macrocephaly, abnormal first or second lumbar verte-
bra with kyphosis, barrel chest, and thickening of the long
bone diaphyses. Progressive arthropathy leads to stiffness
and contracture of large and small joints, with typical claw
hands. Carpal tunnel syndrome is a frequently described
complication. The abdomen may be prominent due to hepa-
tosplenomegaly. All patients experience hearing loss, and
deposition of GAGs in the heart leads to cardiomyopathy
and valvular disease. In severe cases, death occurs in the
first or second decade of life, usually due to obstructive re-
spiratory disease or heart failure (Martin et al., 2008;
Wraith et al., 2008b).
From a neurological perspective, approximately
two-thirds of patients have psychomotor retardation, be-
havioral disturbances and neurological regression. In its at-
tenuated forms, the clinical signs and symptoms of the
disease appear later in life with minimal neurological dys-
function (Neufeld and Muenzer, 2001; Martin et al., 2008;
Beck, 2011; Guelbert et al., 2011). These attenuated pa-
tients have normal intelligence and can survive into adult-
hood. In the severe, neuropathic form of Hunter syndrome,
patients may have primary disease with parenchymal neu-
ral cognitive impairment due to deposition of GAGs in neu-
ral tissue and from other pathophysiologic neurotoxic and
inflammatory disease mechanisms. Patients with non-
neuropathic, attenuated disease may retain normal cogni-
tive abilities yet develop secondary neurological
conditions, such as cervical stenosis, carpal tunnel com-
pression, and hydrocephalus, which result from the accu-
mulation of GAGs rather than primary CNS disease (Holt
et al., 2011a,b).
Diagnosis and Work-Up
Timely diagnosis is the key to improving outcomes
for patients with Hunter syndrome, and diagnosis involves
the examination of disparate clinical factors, biochemical
parameters, and molecular characteristics.
Clinical diagnosis
The clinical diagnosis of Hunter syndrome requires in
the first instance a thorough patient medical and family his-
tory. Pediatricians are likely to be the first clinicians to
316 Giugliani et al.
encounter a patient with Hunter syndrome, and there are a
number of very early signs and symptoms that should
arouse clinical suspicion, for example, lumbar gibbus, re-
current ear infections, hernia, myocarditis, or progressive
hepatosplenomegaly may occur before the age of 6 months.
Other signs and symptoms that are commonly found
(Martin et al., 2008) include the following:
• Facial dysmorphism: coarsening of facial features,
broadened nose with flared nostrils, prominent supraorbital
ridges, large jowls, thickened lips, enlarged protruding
tongue
• Abdominal symptoms: hernia, abdominal disten-
sion due to enlarged liver and spleen
• Respiratory symptoms: recurrent upper airway in-
fection, particularly affecting the ears; sleep apnea
• Skeletal and joint problems: dysostosis multiplex on
radiographic examination, including abnormal bone thick-
ening and irregular epiphyseal ossification in the joints of
the hand, shoulder, and elbow; carpal tunnel syndrome.
Patients with Hunter syndrome often undergo surgi-
cal procedures at a young age, at times before diagnosis, so
Hunter syndrome should be suspected in young children
who have a history of surgical interventions, particularly
for hernia or carpal tunnel syndrome (Mendelsohn et al.,
2010). Thorough documentation of the patient’s surgical
history is an important aspect of the clinical diagnosis of
Hunter syndrome. Mendelsohn and colleagues compared
surgical histories of patients with Hunter syndrome en-
rolled in the Hunter Outcome Survey (HOS), a global regis-
try of patients with Hunter syndrome sponsored by Shire,
with those of the general population and found that more
than 80% of HOS-enrolled patients required surgical inter-
vention and that 57% had undergone surgical intervention
prior to Hunter syndrome diagnosis. These percentages are
considerably higher than what is found in the general popu-
lation (Mendelsohn et al., 2010). A patient with a surgical
history of hernia repair, tympanostomy, adenoidectomy,
and carpal tunnel release should arouse suspicion and
should suggest to the pediatrician that he or she should
carefully evaluate the patient further for additional symp-
toms of Hunter syndrome. An extensive checklist of the
signs and symptoms of Hunter syndrome is shown in Ta-
ble 1 (adapted from the list used by HOS).
The signs and symptoms observed in Hunter syn-
drome vary according to disease severity, as do age of onset
of presenting signs and disease complications (Wraith et
al., 2008b). Symptomatology in Hunter syndrome is best
characterized as a continuum between two extremes, severe
and attenuated. The clinical course is somewhat more pre-
dictable for patients with severe forms of the disease,
whereas the clinical phenotype and progression of attenu-
ated disease is considerably more variable. Individuals with
attenuated disease may still develop symptoms and compli-
cations that lead to significant morbidity and disability.
Manifestations of Hunter syndrome typically emerge
between 18 months and 4 years of age in patients with the
severe phenotype, delayed by approximately 2 years in the
attenuated phenotype (Muenzer et al., 2009). Table 1 also
shows the reported age at onset and prevalence of clinical
features in patients with Hunter syndrome enrolled in HOS.
Due to the often complex progression of symptoms, fre-
quently there is a significant delay between the appearance
of symptoms and the final diagnosis for MPS patients.
Vieira and colleagues found in Brazil that there was an av-
erage delay of 4.8 years for all MPS diseases and it was
even longer for Hunter syndrome. They also reported that,
on average, patients were examined by 4.7 specialists be-
fore a diagnosis was reached (Vieira et al., 2008). Although
the signs and symptoms described Table 1 are very impor-
tant in diagnosing Hunter syndrome, it is as important for
the physician to recognize the pattern of symptoms that are
characteristic of the disease as this is also a crucial part of
the diagnostic process.
Biochemical diagnosis
Urinary GAG analysis
In most cases of MPS, the total urinary GAG (uGAG)
level is elevated (Martin et al., 2008). Excess GAGs in the
urine indicate the likely presence of an MPS, but is not a de-
finitive diagnostic test for Hunter syndrome, and other tests
should be performed. Tests for uGAG analysis can be quan-
titative (i.e., measurement of total uGAGs, usually with the
dimethylene blue method (de Jong et al., 1989) or qualita-
tive (GAG electrophoresis or chromatography) (Wraith et
al., 2008b); however, uGAG testing methods are plagued
by a lack of sensitivity and can present false-negative re-
sults (Martin et al., 2008).
It is also important to note that uGAG testing, despite
being relatively simple, is not available in all Latin Ameri-
can countries. This is an issue as the transport of urine sam-
ples across international borders can be challenging, poten-
tially requiring long bureaucratic processes that could
impair sample viability. Also, even if uGAG testing is
available, it may not be covered by public or private health
insurance plans.
Enzyme assay
If uGAG analysis reveals elevated dermatan and
heparan sulfates, the definitive biochemical diagnosis of
Hunter syndrome can be established through blood enzyme
testing. Enzyme assays should be performed to determine
deficiency of I2S enzyme activity in plasma leukocytes or
fibroblasts (Wraith et al., 2008b; Guelbert et al., 2011;
Scarpa et al., 2011). Choice of assay depends on the testing
facility, but leukocytes are usually preferred when avail-
able (Martin et al., 2008). Analysis of dried blood spots on
filter paper is an especially useful screening tool, particu-
larly in areas where transport of cells or serum samples is
challenging (Civallero et al., 2006; Dean et al., 2006; Mar-
tin et al., 2008).
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Molecular diagnosis
Although not usually needed to establish a diagnosis,
molecular genetic testing of the I2S gene may be useful
(Scarpa et al., 2011). More than 300 mutations of the I2S
gene have been described (Froissart et al., 2002; Jurecka et
al., 2012). A detailed pedigree analysis should be com-
pleted if an I2S gene mutation is identified, and genetic
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Table 1 - Major signs and symptoms of Hunter syndrome. Adapted from (Wraith et al., 2008a,b; Keilmann et al., 2012).
Organ system/anatomical
region
Signs and symptoms Prevalence (%) Median age of onset (y)
Head and neck Facial features consistent with Hunter syndrome (facial
dysmorphia, coarse facies, macrocephalus, hydrocephalus)
95 2.4
Eye Papilledema -
Retinal degeneration -
Mouth Enlarged tongue (macroglossia) 70 3.4
Ear Otitis media 72 1.9
Ventilation tubes 50 3.5
Hearing loss 67 4.8
Hearing aids 41 6.6
Tinnitus 2 13.3
Vertigo 3 14.6
Nose Nasal obstruction 34 2.0
Rhinorrhea -
Throat Enlarged tonsils/adenoids 68 2.9
Chest/lungs Dyspnea -
Chronic cough/bronchitis -
Sleep apnea -
Difficulty with intubation/inability to intubate -
Cardiovascular Murmur 62 5.8
Arrhythmia 4 6.3
Tachycardia 7 11.3
Bradycardia 2 13.9
Hypertension 6 11.4
Cardiomyopathy 8 4.8
Congestive heart disease 4 8.9
Valve disease 57 6.1
Myocardial infarction 0.5 44.9
Peripheral vascular disease 2 9.3
Gastrointestinal Abdominal hernia 78 1.3
Hepatosplenomegaly 89 2.8
Diarrhea -
Skin Hunter lesions (i.e., pebble lesions) -
Skeletal Joint stiffness and limited function/contracture 84 3.6
Kyphosis/scoliosis 39 5.0
Neurological Hydrocephalus 17 5.8
Seizures 18 9.3
Swallowing difficulties 27 8.9
Carpal tunnel syndrome 25 7.9
Impaired fine motor skills 33 4.0
Hyperactivity 31 3.5
Frequent chewing 13 6.8
Cognitive problems 37 3.2
Behavioral problems 36 3.7
counseling should be offered to all family members (Guel-
bert et al., 2011; Scarpa et al., 2011). A distal pseudogene
(IDS2) containing highly homologous sequences is found
downstream of the IDS gene. This can complicate molecu-
lar analysis and for this reason genomic DNA sequencing is
often followed by cDNA analysis (Scarpa, 2011).
Identification of an I2S gene mutation in affected pa-
tients can facilitate (Guelbert et al., 2011):
• Precise molecular diagnosis
• Identification of female carriers
• Initiation of genetic counseling
• Timely and precise prenatal diagnosis
• Evaluation of genotype-phenotype correlations.
Prenatal testing allows for early and rapid diagnosis
of affected fetuses and is available via enzyme assay of
I2S in uncultured chorionic villi sampling at 11 weeks’
gestation, or by amniocentesis at 16 weeks. Preimplan-
tation genetic diagnosis can identify affected embryos in
at-risk pregnancies. Prenatal enzymatic assays are of two
types: (1) enzyme assay of I2S in all at-risk pregnancies
when mutation is not known, and (2) molecular study
when the mutation is known. Chromosomal testing for fe-
tal sex determination should be conducted in conjunction
with enzymatic assays (Wraith et al., 2008b; Guelbert et
al., 2011). Figure 1 shows a diagnostic algorithm for
Hunter syndrome.
Basic Clinical Evaluation and Management
Upon diagnosis of Hunter syndrome, the clinical eva-
luation endeavors to determine the severity of disease and
the extent of multisystem involvement. Table 2 reviews the
relevant assessments for patients diagnosed with Hunter
syndrome. As the clinical manifestations of Hunter syn-
drome are multisystemic, a multidisciplinary approach is
required to proactively recognize and manage complica-
tions (Muenzer et al., 2009; Guelbert et al., 2011). The
multidisciplinary care team should include specialists as
appropriate to meet each individual patient’s needs. Rou-
tine assessment of the various affected organs and systems
is necessary, and each specialist in the multidisciplinary
team should oversee continuing evaluations once a clinical
problem is identified. This helps to optimize the quality of
life for patients and their families (Muenzer et al., 2009;
Guelbert et al., 2011). Figure 2 shows images of two Hunter
syndrome children, one with a severe, and one with an at-
tenuated phenotype.
Neurological
CNS complications in patients with Hunter syndrome
can include seizures, spinal cord compression with result-
ing cervical myelopathy, and hypertrophic pachymenin-
gitis cervicalis. Standard anticonvulsant treatment can be
administered for tonic-clonic seizures (Holt et al., 2011a;
Scarpa et al., 2011). Failure to treat cervical myelopathy
can result in irreversible cord damage; thus, when symp-
toms manifest, prompt, careful cervical decompression
should be performed by an experienced team to help avoid
severe neurological consequences (Wraith et al., 2008b;
Scarpa et al., 2011). Early aggressive treatment is indicated
in patients with attenuated disease who have hypertrophic
pachymeningitis cervicalis and cervical compression
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Figure 1 - Diagnostic algorithm for Hunter syndrome. From (Scarpa et al.,
2011, copyright © 2011, BioMed Central Ltd.). GAGs, glycosamino-
glycans; LSD, lysosomal storage disorder; MPS, mucopolysaccharidosis.
secondary to hyperplasia of the transverse ligaments. Par-
ticular care should be taken to prevent cord compression
during general anesthesia (Muenzer et al., 2009).
Carpal tunnel syndrome, a common peripheral ner-
vous system complication in patients with attenuated forms
of the disease, warrants prompt evaluation and treatment.
Frequently it is not easy to determine if the patient is experi-
encing pain from carpal tunnel syndrome and it can also
represent an underlying cause of behavioral problems in
patients with Hunter syndrome. As noted in Table 2, nerve
conduction studies should be undertaken in patients at 4-5
years of age and every 1-2 years thereafter (Muenzer et al.,
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Table 2 - Suggested evaluations for patients with Hunter syndrome. Adapted from (Wraith et al., 2008b; Muenzer et al., 2009; Guelbert et al., 2011).
Organ System/involvement Assessment Frequency recommendationa
Neurological
General • Neurophysiologic exams
• EEG
Yearly
Hydrocephalus • MRI/CT of the head +/- gadolinium
• LP measurement of CSF pressure
Every 1-3 years
Spinal cord compression • MRI cervical spine Every 1-3 years
Atlantoaxial instability • Cervical spine flexion/extension Every 2-3 years, and before general anesthesia
Progressive cognitive involvement • Neurobehavioral Yearly
Carpal tunnel syndrome • Nerve conduction At 4-5 years old, then at 1- or 2-year intervals
• Hand function tests Yearly
Cardiovascular
Myocardiopathy
Valvular dysfunction
• ECHO/ECG
• Holter (conduction irregularities)
Yearly
Auditory • Otologic and audiologic
• Audiometry
• Phonoaudiology
Every 6-12 mo
Respiratory • Pulmonary function
° Chest x-ray
° Oxygen saturation
° Sleep study to detect OSA
° 6MWT
° 3-minute stair climbing test
Upon diagnosis or when patient is old enough to
cooperate, then yearly
• Sleep study Every 3-5 years, then upon suspicion of OSA
• Bronchoscopy As necessary to evaluate pulmonary involvement or
in preparation for general anesthesia
Musculoskeletal • JROM Yearly
• Bone mapping, radiograph of
° Spine and hip
° Thoracic
° Hands
° Long bones
Upon diagnosis and thereafter in response to signs
and symptoms
Ophthalmologic • Standard ophthalmologic examination
° Visual acuity
° Visual field
° Biomicroscopy
° Intraocular pressure
° Electroretinography
Yearly
Psychiatric • Clinical evaluation
• Psychosocial/environmental evaluation
According to clinical judgment
Dental • Standard dental care Every 6 mo
Abdominal Every examination Every examination
Inguinal hernia • Clinical evaluation
Hepatosplenomegaly • Clinical evaluation
aRecommendations upon diagnosis, and thereafter as indicated.
6MWT, 6-minute walk test; CSF, cerebrospinal fluid; CT, computed tomography; ECG, electrocardiogram; ECHO, echocardiogram; EEG, electroen-
cephalography; JROM, joint range of motion; LP, lumbar puncture; MRI, magnetic resonance imaging; OSA, obstructive sleep apnea.
2009). In most patients, surgical decompression of the me-
dian nerve at an early stage of involvement results in partial
or complete improvement (Wraith et al., 2008b).
Cardiovascular
Cardiac valve replacement surgery may be needed in
some patients with Hunter syndrome, and monitoring is es-
sential through annual cardiac evaluations that include
echocardiograms (ECHO) and/or electrocardiograms
(ECG). Prophylaxis for bacterial endocarditis should be ad-
ministered when indicated (Wraith et al., 2008b). The cur-
rent standard of cardiac care for MPS focuses on pharmaco-
logical intervention for heart failure and cardiac surgery.
Recent studies in patients with MPS suggest that systemic
therapies, such as ERT, may improve cardiovascular clini-
cal outcomes in patients with Hunter syndrome, particu-
larly in patients who receive early intervention (Guffon et
al., 2009; Prasad and Kurtzberg, 2010; Braunlin et al.,
2011).
Ophthalmic
As with other aspects of Hunter syndrome, early rec-
ognition and treatment of ophthalmic complications are
critical. Deposition of GAGs within retinal pigment epithe-
lial cells and in the interphotoreceptor matrix results in
retinopathy, which leads to progressive photoreceptor loss,
and retinal degeneration and dysfunction (Ferrari et al.,
2011). Glaucoma is rarely present (Wraith et al., 2008b) but
if detected should be treated promptly (Guelbert et al.,
2011). Patients should undergo annual ophthalmological
evaluations that include measurement of intraocular pres-
sure; corrective lenses should be prescribed as appropriate
(Wraith et al., 2008b).
Audiologic
Because hearing loss is nearly universal in Hunter
syndrome, the use of hearing aids is an important aspect of
disease management (Muenzer et al., 2009; Keilmann et
al., 2012). Hearing loss can contribute to behavioral prob-
lems and learning difficulties. Patients who experience
hearing loss can become socially disconnected when hear-
ing aids are not used. The resulting behavioral effect is sim-
ilar to that observed in autism spectrum disorders.
Chronic otitis media is a common feature of Hunter
syndrome and contributes to conductive hearing loss. Rou-
tine otologic and audiologic evaluations should be per-
formed at least every 6-12 months, and recurrent ear infec-
tions should be treated as appropriate. In patients with
hearing loss secondary to persistent middle ear effusion,
clinicians should discuss the use of hearing aids and/or
myringotomy with placement of ventilating tubes to im-
prove hearing (Peck, 1984; Muenzer et al., 2009). The use
of hearing aids is encouraged, and both treatments are ef-
fective, but hearing aids are preferred for children with sig-
nificant comorbidities (Muenzer et al., 2009; Scarpa et al.,
2011).
Dental
Standard dental care is recommended whenever pos-
sible in patients with Hunter syndrome, with evaluation ev-
ery six months (Muenzer et al., 2009). Due to the limited
maximum opening of the jaw, routine dental procedures
may be difficult, and some will require general anesthesia,
which poses particular risks in patients with Hunter syn-
drome. Delayed dental eruption has been reported, particu-
larly with the first permanent molars. This is thought to be
associated with areas of bone involvement that resemble
dentigerous cysts (Liu, 1980; Muenzer et al., 2009). More-
over, surgical procedures may be difficult due to anatomic
alterations caused by the disease.
Respiratory
Episodes of significant hypoxia should be managed
through use of continuous or bilevel positive airway pres-
sure devices. However, in severely affected patients who
do not tolerate this treatment, supplemental oxygen alone
may be an acceptable alternative. In patients with docu-
mented hypercapnia, supplemental oxygen should be used
with caution (Wraith et al., 2008b). Tonsillectomy and
adenoidectomy are often performed to correct Eustachian
tube dysfunction and to decrease airway obstruction. Se-
verely affected patients also tend to have frequent ear infec-
tions and constant rhinorrhea; therefore, early placement of
ventilating tubes is recommended (Wraith et al., 2008b;
Guelbert et al., 2011). Pathological changes and obstruc-
tion in the upper airways, in addition to the short neck and
jaw immobility seen in patients with Hunter syndrome
makes general anesthesia a high risk procedure. It is there-
fore good practice to consider local or regional anaesthesia
where possible (Scarpa et al., 2011).
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Figure 2 - Children with Hunter syndrome. A: a 2-year-old with a severe
phenotype; B: an adult male with an attenuated phenotype.
Gastrointestinal
Abdominal hernias should be corrected surgically.
Diarrhea can be managed with diet and antimotility drugs
(Wraith et al., 2008b; Guelbert et al., 2011). According to
2005 World Health Organization guidelines, home therapy
to prevent dehydration and manage diarrhea includes intake
of plain water and electrolyte solutions. Commercial car-
bonated beverages, fruit juices, sweetened tea, coffee, and
medicinal teas should be avoided. As patients with Hunter
syndrome age, physical inactivity and loss of muscle
strength can result in constipation. Constipation can be
managed through adequate hydration, and dietary and be-
havior modification. Oral laxative medications to treat con-
stipation include high-dose mineral oil, polyethylene gly-
col electrolyte solutions, or a combination of both. Other
options include high-dose magnesium citrate, magnesium
hydroxide, sorbitol, lactulose, senna, or bisacodyl (Green-
wald, 2010).
Musculoskeletal/orthopedic
Orthopedic complications can lead to significant dis-
ability (Wraith et al., 2008b). Data from HOS showed that
79% of enrolled patients had skeletal manifestations and
25% had abnormal gait. Furthermore, joint range of motion
(JROM) was restricted for all joints assessed, which in-
cluded elbow, shoulder, hip, knee, and ankle (Link et al.,
2010). Destructive arthropathy is debilitating and quite dif-
ficult to manage (Guelbert et al., 2011). Although the role
of physical therapy in Hunter syndrome is not well studied,
JROM exercises may offer some benefit and should be
started at an early age to preserve joint function and to slow
progression in patients with significant restriction of joint
movement (Wraith et al., 2008b).
Additional assessments
Additional assessments include evaluations of devel-
opment (e.g. Denver II, Developmental Quotient, Intelli-
gence Quotient etc.), function, independence, and daily
activities. In Latin America, the FIM (Functional Inde-
pendence Measure) and PEDI (Pediatric Evaluation of Dis-
abilities Inventory) scales can be employed. The 6-minute
walk test (6MWT) (American Thoracic Society, 2002)
should be performed upon diagnosis and every 6-12
months depending on treatment regimen.
The multidisciplinary care team may also include
other specialists, such as a dietician for nutritional support,
speech language pathologists/audiologists, psychothera-
pists, and physiotherapists. It is also important to highlight
the role of patient and family support groups and associa-
tions that can often provide good practical advice and emo-
tional support.
Treatments
Enzyme replacement therapy
Enzyme replacement therapy (ERT) with recombi-
nant human I2S (idursulfase) is available for patients with
Hunter syndrome. The US Food and Drug Administration
and the European Medicines Agency approved idursulfase
for treatment of patients with Hunter syndrome based on re-
sults of a pivotal phase 2/3 randomized, double-blind, pla-
cebo-controlled clinical trial in 96 patients with Hunter
syndrome aged 5-31 years (Muenzer et al., 2006). The pri-
mary endpoint of the study was a two-component compos-
ite of the 6MWT and predicted forced vital capacity (FVC).
After 53 weeks, patients receiving a weekly regimen of
idursulfase experienced a statistically significant mean
44.3-m ( 12.3 m) improvement in the 6MWT compared to
patients receiving placebo, who experienced a mean im-
provement of 7.3 m ( 9.5 m) (p = 0.0131). Those on
weekly idursulfase also showed a mean improvement of
3.45% ( 1.77%) in predicted FVC compared to 0.75%
( 1.71%) for those on placebo (p = 0.065), and a mean
220-mL ( 50 mL) increase in absolute FVC, compared to
60 mL ( 30 mL) for those on placebo (p = 0.0011). In addi-
tion, patients treated with idursulfase experienced improve-
ments in liver and spleen volume and in uGAG excretion.
In general, treatment with idursulfase was well tolerated;
however, infusion-related reactions did occur (experienced
by 69% of patients on idursulfase and 66% of patients on
placebo). The risk of infusion related reactions appears to
be greatest in the first six months of treatment (Miebach,
2009). Anaphylactoid reactions, which have the potential
to be life threatening, have been observed in some patients.
Idursulfase is administered weekly as an intravenous (IV)
infusion at a dose of 0.5 mg/kg (Shire Human Genetic Ther-
apies, 2011). As idursulfase does not cross the blood-brain
barrier, the challenges of treating the neurological features
of Hunter syndrome remain.
Criteria for ERT
Despite the approved guidelines that state that ERT
should be offered to all patients older than five years with
an attenuated phenotype, Latin American specialists who
have experience with treatment are increasingly convinced
that ERT should be started as early as possible. A recent
study has demonstrated that in 28 boys, aged 1.4-7.5 years,
idursulfase safety and tolerability was similar to that previ-
ously reported in males older than five years (Giugliani et
al., 2013). Indeed, ERT should be considered for all symp-
tomatic heterozygous patients who may benefit from ther-
apy, as supported by evidence from clinical trials (6MWT,
reduction of organomegaly, respiratory improvement) and
case reports. In patients with the severe phenotype and evi-
dence of significant cognitive degeneration, the decision to
initiate ERT rests with the treating clinicians, the institu-
tion’s ethics committee, and the patient’s family (Guelbert
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et al., 2011). An expert panel consensus, commenting on
the role of ERT in patients with severe Hunter syndrome,
stated that “all previously diagnosed, symptomatic patients
in whom there is an expectation that ERT will alter the
course of the somatic involvement are also candidates for a
trial of idursulfase treatment, even if cognitive impairment
is already evident” (Muenzer et al., 2012). In discussion
with government and health authorities when making deci-
sions in the absence of robust scientific evidence, experi-
enced physicians can provide useful advice to aid a final
decision.
Female patients with Hunter syndrome show attenu-
ated and severe phenotypes, and disease progression shows
a similar clinical course and prognosis as for male patients;
criteria for treatment is the same as for males. Although
data are extremely limited, results from case studies sug-
gest that ERT may help to stabilize the progression of dis-
ease in female patients (Jurecka et al., 2012).
When to initiate ERT
Initiation of ERT should occur as early as possible.
Patients aged  5 years were not included in the pivotal tri-
als of ERT with idursulfase (Muenzer et al., 2006, 2007),
but results from a recent study demonstrate that ERT is sim-
ilarly safe in children younger than five years compared to
those older than five years (Giugliani et al., 2013). A recent
consensus statement underscores the need for timely indi-
vidualized treatment. In patients with an attenuated pheno-
type, the expert panel noted the importance of considering
ERT, even if the rate or severity of cognitive decline is not
yet apparent (Muenzer et al., 2012).
Benefits of early treatment with ERT
The benefit of early intervention with ERT is sup-
ported by data from recent studies. Alcalde-Martín and col-
leagues analyzed HOS data from 6 patients with Hunter
syndrome who were younger than five years at ERT initia-
tion (Alcalde-Martin et al., 2010). All patients showed neu-
rological abnormalities at baseline. After eight months of
weekly ERT, results showed reduced uGAG levels and re-
duced spleen (n = 2) and liver size (n = 1). In addition,
growth (height) was maintained within the normal range
during ERT, and joint mobility either stabilized or im-
proved. Safety findings were similar to those observed in
older patient populations. A case report from Poland sug-
gests the possibility that early initiation of ERT may mark-
edly slow or prevent the development of some irreversible
manifestations of Hunter syndrome, including coarse facial
features, joint disease, and cardiac function (Tylki-
Szymanska et al., 2012).
Schulze-Frenking and colleagues, conducting a retro-
spective analysis of patients with attenuated phenotype
Hunter syndrome who were enrolled in a clinical trial to de-
termine effects of ERT on linear growth, noted that ERT
appeared to have a positive influence on growth. The great-
est benefit was observed in patients beginning ERT before
age 10 years, supporting the recommendation that ERT
should be started as early as possible (Schulze-Frenking et
al., 2011).
Muenzer and colleagues evaluated 124 patients aged
< 6 years enrolled in HOS. The mean age at start of ERT
was 3.6  1.6 years, with a mean duration of treatment of
22.9  14.6 months. After at least six months of ERT with
idursulfase, mean uGAG levels decreased from 592 
188 g/mg to 218  115 g/mg creatinine (p < 0.0001,
n = 34). Furthermore, liver size, as estimated by palpation,
also decreased significantly (p = 0.005, n = 23). No new
safety concerns were noted in patients younger than six
years (Muenzer et al., 2011).
In a recent, open-label, study that evaluated safety
and clinical outcomes in 28 boys aged 1.4 to 7.5 years, the
safety of idursulfase ERT over one year was observed to be
similar to that previously reported in the 2006 pivotal trial.
Exploratory outcomes showed that, at week 18, mean nor-
malized uGAG had decreased 49.2% compared to baseline
values, and mean index of liver size and spleen volumes de-
creased by 20.1% and 23.3%, respectively. These reduc-
tions were largely maintained through to week 53 (week 53
decreases vs. baseline were 54.4%, 17.4%, and 20.6% for
mean normalized uGAG, index of liver size, and spleen
volume, respectively) (Giugliani et al., 2013).
Communicating with patients’ families
Effective communication with patients’ families is
essential. Although ERT may have benefits for many pa-
tients, treatment of patients with severe CNS involvement
remains problematic. Clinicians should communicate
clearly with patients’ families regarding the limitations of
ERT. Moreover, clinicians must help families of patients
with severe forms of the disease establish realistic expecta-
tions, as these expectations may influence the decision of
whether or not to initiate ERT. Communication with the
family is also important in assessing the patient’s response
to ERT; an improvement in quality of life as perceived by
the family should be considered a benefit of treatment in
patients with severe disease (Muenzer et al., 2012). Pa-
tient/family associations and support groups can be particu-
larly important in helping families obtain realistic expecta-
tions for ERT, as families’ hopes are frequently much
greater than the likely benefit from ERT.
Monitoring of patients receiving ERT
In patients receiving ERT, it is important to monitor
uGAG levels, as well as the patient’s weight to maintain the
standard idursulfase dose of 0.5 mg/kg, to evaluate treat-
ment and patient response to treatment. These and other as-
sessments for patients receiving ERT are listed in Table 3.
In patients who are not candidates for ERT (due to ad-
vanced disease, pregnancy/lactation, or other significant
comorbidities), assessments should be conducted as shown
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in Table 2 (Wraith et al., 2008b; Muenzer et al., 2009;
Guelbert et al., 2011).
Management of ERT infusion-site reactions
Idursulfase is administered intravenously at
0.5 mg/kg per week (Shire Human Genetic Therapies,
2011). Clinicians administering ERT to patients with
Hunter syndrome, either in the clinic or at home, should be
familiar with the timing, nature, and recommended man-
agement of infusion-associated reactions (Burton et al.,
2010). Two types of infusion-site reactions have been doc-
umented: those occurring during the infusion and those oc-
curring  12 h after the infusion (Wraith et al., 2008b).
Most infusion-site reactions occur during the first three
months of treatment; however, in rare cases, infusion-site
reactions have occurred after more than six months of ERT
(Burton and Whiteman, 2011).
In an analysis of data from the HOS, researchers
noted that most infusion-site reactions were mild to moder-
ate in severity (Burton and Whiteman, 2011). Typical reac-
tions during infusion include fever, chills, and urticaria,
which can be managed by temporarily stopping the infu-
sion, administering acetaminophen and antihistamines, and
restarting the infusion at a slower rate after 30 min or longer
(Wraith et al., 2008b; Burton and Whiteman, 2011). At
subsequent ERT infusions, the treating physician may de-
cide to premedicate the patient with acetaminophen and an-
tihistamines one hour prior to infusion. In patients who
experience reactions despite premedication, pretreatment
with corticosteroids should be considered (Wraith et al.,
2008b).
Reactions occurring  12 h after the infusion typically
consist of a sunburn-like rash and mild wheezing. Rash can
be managed with acetaminophen and antihistamines and/or
corticosteroids. Management of wheezing requires treat-
ment with bronchodilators and, possibly, oxygen
supplementation (Wraith et al., 2008b).
Analysis of HOS data detected immunoglobulin G
(IgG) antibodies to idursulfase in 51% of patients on ERT
(Burton and Whiteman, 2011) and analysis of the pivotal
II/III data has also showed that about half of patients (atten-
uated phenotype, five years or older) developed IgG anti-
bodies, with about a third becoming persistently antibody
positive, and one fifth developing neutralizing antibodies.
Infusion-associated reactions were about twice as likely to
occur in those patients who become antibody positive on
treatment, but most of the risk for reactions occurs before
the antibodies have developed, so this data leads to no mod-
ifications to the guidelines for management of infu-
sion-associated reactions (Barbier et al., 2013).
ERT home therapy
Most patients receive ERT infusions at dedicated
treatment centers. However, lack of transportation, missing
school and work, and living in remote areas may present
significant challenges for patients and their families.
Studies have shown that receiving infusions at home can be
beneficial in terms of reducing stress, improving adher-
ence, providing greater convenience, and having less im-
pact on family life (Milligan et al., 2006; Burton et al.,
2010; Scarpa et al., 2011).
In general, home infusion of idursulfase may be con-
sidered for patients who have received several months of
treatment in the clinic and who are tolerating their infusions
well. More details of the considerations required for home
treatment are shown in Table 4. Regular administrations are
usually performed by a nurse (Burton et al., 2010). In some
Latin American countries home therapy is already in
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Table 3 - Monitoring of patients with Hunter syndrome aged  5 years receiving ERT. Adapted from (Wraith et al., 2008b; Muenzer et al., 2009;
Guelbert et al., 2011).
Organ system/involvement Assessment Recommendationa
Medical history Clinical evaluation, including developmental milestones Every 6 mo
Physical examination Clinical evaluation, including height, weight, head circumference, BP,
neurological examination
Every 6 mo
Infections/surgeries Clinical evaluation Every 6 mo
Neurological Cognitive assessment Every 12 mo
Cardiovascular Echocardiogram, ECG Every 12 mo
Pulmonary Spirometry Every 12 mo
Musculoskeletal JROM Every 12 mo
6MWT Every 6 mo
General ERT status: start date, dosage, any missed infusions Every 6 mo
uGAG level Every 6 mo
Antibody testing Prior to ERT start, then every 6 mo
aConduct upon enrollment, and monitor thereafter, as indicated.
6MWT, 6-minute walk test; BP, blood pressure; ECG, electrocardiogram; ERT, enzyme replacement therapy; uGAG, urinary glycosaminoglycan;
JROM, joint range of motion.
operation and patients are receiving treatment at home.
Home therapy is usually more challenging in Latin Amer-
ica than in developed countries as home care teams are
scarce or not available in many countries, and patients’
home conditions may not be suitable for safe storage of
drugs or for performing infusions.
Patients younger than five years receiving ERT
Recommendations for follow-up in patients aged  5
years mirror those for older patients. Special care should be
taken in monitoring since age-related challenges could
arise that require adaptations to the monitoring regimen.
Continued monitoring of routine developmental
milestones is required to determine the long-term effects of
idursulfase on linear growth and weight (Alcalde-Martin et
al., 2010). Monitoring of GAG levels in urine is important
because available data and clinical observations suggest
that uGAG levels are higher in young patients (aged less
than five or six years) with Hunter syndrome compared
with older patients (Muenzer et al., 2011).
A particular challenge when monitoring very young
patients with Hunter syndrome is that functional testing re-
quires their cooperation, especially when assessing pulmo-
nary function or mobility (Muenzer et al., 2011). Thus, in
children aged  5 years, interpreting data from JROM tests
and determining reliability can be difficult; the 6MWT may
not be performed consistently, making evaluation of results
problematic; and pulmonary spirometry can be difficult to
perform and interpret if a child chooses not to cooperate.
Furthermore, difficulties exist with respect to abdominal
imaging in very young children, making it hard to deter-
mine improvements in organomegaly (Alcalde-Martin et
al., 2010).
When to stop or suspend ERT
In general, ERT should be discontinued or suspended
in the following circumstances (Guelbert et al., 2011):
• Severe or advanced disease that does not improve
with ERT
• Severe infusion-associated reactions that cannot be
managed with recommended premedication
• Life-threatening comorbidities (review on a case-
by-case basis)
• Pregnancy/breastfeeding
• Incurable disease unrelated to Hunter syndrome
(e.g., terminal cancer)
In patients with severe Hunter syndrome, discontinu-
ation of ERT should be considered in the following circum-
stances (Muenzer et al., 2012):
• After a trial of at least 6-12 months if no benefit is
evident. Note that improvement in quality of life as per-
ceived by the patient’s family should be considered a bene-
fit of treatment
• Exacerbated behavioral difficulties as a result of
ERT
• Neurological decline progressing to a severe degree
Other Treatment Options
Transplantation
Although hematopoietic stem cell transplantation
(HSCT) has been successful in modifying the course of dis-
ease in patients with other LSDs (i.e., MPS I and MPS VI),
data in the literature do not seem to support the benefits of
HSCT for Hunter syndrome (Vellodi et al., 1992, 1999;
Wraith et al., 2008b). Similarly, data on bone marrow
transplantation and umbilical cord blood transplantation
(UCBT) are scarce and based on published individual case
studies or small case series (Scarpa et al., 2011). Research
continues into novel treatment approaches, such as micro-
transplantation.
In Latin America there are particular challenges due
to the difficulty of finding donors (insufficient donor regis-
tries) and obtaining timely transplantations. There is also a
lack of experience in many bone marrow transplanta-
tion/HSCT centers in dealing with patients with metabolic
diseases.
Ongoing Research
Intrathecal ERT and fusion proteins to overcome the
blood-brain barrier
Research seeks to address the challenges of treating
the neurological complications of Hunter syndrome, with a
focus on developing well-tolerated therapies that can cross
the blood-brain barrier. Investigational experiments in
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Table 4 - Minimum requirements for transfer of patients to ERT home
therapy. Adapted from (Burton et al., 2010).
Patients
• Well established on idursulfase therapy
• Free of infusion-associated reactions
• Aged 2 years or older
• Stable airway diseasea
• Established IV access
Family
• Should be made aware of relative risks/benefits of home therapy
Home Care Team
• Meet patient prior to transfer
• Assess home environment prior to patient transfer
• Skilled in giving infusions and managing infusion-associated
reactions
• Experienced in management of patients with LSDs
• Family doctor should be informed of patient transfer to ERT home
therapy
aHome treatment is contraindicated in patients with respiratory infections
or other current illnesses.
ERT, enzyme replacement therapy; IV, intravenous; LSDs, lysosomal
storage disorders.
animal models of LSDs, including Hunter syndrome, have
shown that ERT with a different formulation of idursulfase
to that used in conventional ERT delivered via the intra-
thecal route distributes throughout the CNS, penetrates
brain tissue, and promotes clearance of lysosomal storage
material (Dickson, 2009). Clinical trials are currently in-
vestigating intrathecal ERT in patients with MPS II (see,
for example, U.S. National Institutes of Health
ClinicalTrials.gov identifiers NCT00920647 and
NCT02055118).
Another approach to enabling therapeutic proteins to
cross the blood-brain barrier is by using fusion proteins. In
this approach, the therapeutic protein is fused with another
protein that binds to receptors that stimulate its transport
across the blood-brain barrier via active receptor-mediated
transport. Intravenous administration of a fusion protein
consisting of the I2S enzyme with a monoclonal antibody
to the human insulin receptor has been reported to produce
therapeutic concentrations of I2S in the brain of Rhesus
monkeys (Lu et al., 2011).
Biomarkers
To date, blood enzyme levels and total uGAGs are the
only commonly used biomarkers for diagnosis of MPS.
There is no consensus, however, on the use of GAGs to as-
sess treatment efficacy; however, some experts assert that
in addition to clinical efficacy, the biochemical effect of
idursulfase is noted by a dose-dependent reduction in
uGAG excretion (Clarke, 2008; Clarke et al., 2012). Al-
though measurement of uGAG levels may provide some
nuanced information regarding treatment efficacy, the in-
formation is nonspecific and subject to variability depend-
ing on the age and hydration status of the patient, features
that limit the utility of this biomarker (Langford-Smith et
al., 2011).
There is great hope that new biomarkers will provide
greater specificity and ultimately help to improve outcomes
in patients with Hunter syndrome. One such biomarker is
heparin cofactor II-thrombin complex (HCII-T), which was
recognized as a biomarker for MPS diseases in 2008
(Randall et al., 2008). A subsequent investigation of blood
samples from patients with MPS diseases found that serum
HCII-T levels are elevated prior to ERT treatment of
Hunter syndrome and that levels decrease in response to
treatment (Langford-Smith et al., 2011). These results sug-
gest that HCII-T might be a suitable biomarker for the diag-
nosis and monitoring of immediate treatment outcomes,
whereas the ratio of urine dermatan sulfate to chondroitin
sulfate may correlate with long-term clinical outcomes.
Continued research is needed to determine the clinical util-
ity of new biomarkers.
Social Support
Social partnership
The multisystemic nature of Hunter syndrome under-
scores the importance of a multidisciplinary team ap-
proach. In addition to medical specialists, the patient’s care
team should include the coordinating support of a social
worker. This is important in Latin America, where there is a
high percentage of the population with limited economic
and cultural resources, far from minimum standards of wel-
fare.
As part of the multidisciplinary care team, the social
worker must act responsibly to effectively coordinate so-
cial services to enhance individual capabilities and collec-
tive resources so as to best meet the needs of patients and
their families. Education and training, including the cre-
ation of action strategies, play important roles in coordinat-
ing the work of the entire care team to optimize patient
outcomes. The social worker plays a vital coordinating role
in the care team to bridge the gap between physicians, pa-
tients, and families, and to facilitate optimal treatment. The
social worker must assess the socioeconomic needs of each
patient and intervene, as appropriate, to overcome the ef-
fects of social, cultural, and economic obstacles to meet
therapeutic goals.
The role of the social worker includes:
• Liaising with patients and their families and/or pre-
paring them for the challenges of living with Hunter syn-
drome
• Facilitating access to adequate medical care
• Encouraging patients and their families to be active
participants in attaining therapeutic goals
• Communicating with other members of the care
team about the patient’s individual challenges, while con-
sidering the patient’s socioeconomic situation
• Informing patients and their families regarding their
rights to social support and the resources available in their
respective countries
• Talking with family members to help determine the
patient’s needs for support during treatment.
Resources for Patients and Families
Supportive care is an important component of treat-
ment for patients with Hunter syndrome and their families.
A number of resources are available to guide clinicians and
family members in Latin America; for example, in Brazil
the MPS Brazil Network (www.mps.ufrgs.br) provides in-
formation on MPS diseases for families and health profes-
sionals and also supports diagnostic intervention (see
Supplementary Material Table S1).
Conclusion
Hunter syndrome is a rare, X-linked metabolic disor-
der that affects multiple organ systems in a progressive
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manner. Patients with Hunter syndrome experience a wide
spectrum of clinical manifestations that require manage-
ment through a multidisciplinary care team. Early diagno-
sis of the disease and timely initiation of available treat-
ments are key factors that may help to slow disease
progression and lead to improved quality of life for patients
and their families. Clinicians in Latin America should con-
sider current data on the clinical aspects, diagnosis, and
treatment of Hunter syndrome; furthermore, the patient’s
care team must coordinate efforts to employ available re-
sources to optimize patient outcomes.
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